EGFR and lung carcinoma: Therefore, despite the lower response of PD-1/PD-L1 therapy in EGFR mutant compared with EGFR wild-type patients, higher PD-L1 expression still indicates a better response to anti-PD-1/PD-L1 inhibitors in EGFR mutant advanced lung cancer patients who acquired EGFR-TKI resistance.